Molecularly Tailored Therapy for Pancreas Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-12-31

Study Completion Date

2018-01-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patient therapy is tailored according to the molecular profile of the patient's tumor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

NCT01488552

Stage IV Pancreatic Cancer

COMPLETED PHASE1/PHASE2

Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma

NCT02172976

Resectable Prancreas Carcinoma

COMPLETED PHASE2/PHASE3

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

NCT06941857

Pancreatic Cancer

RECRUITING PHASE2

Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

NCT03703063

Pancreatic Adenocarcinoma

UNKNOWN PHASE1

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

NCT00593008

Pancreatic Adenocarcinoma

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is for patients with metastatic pancreatic cancer (cancer that has spread to other parts of the body). The purpose of this study is to determine whether molecularly tailored therapy can improve the effectiveness of standard chemotherapy combinations for patients with metastatic pancreatic cancer. A series of special tests will be performed on a sample of tumor, and based on the results subjects will be assigned to one of seven chemotherapy treatments, with each being the combination of two standard chemotherapies. Each of these combinations has been safely used in patients with pancreatic or other types of cancer. The purpose of this study is to to determine the ability to personalize therapy in this manner, and to determine how many patients a larger study would need. A second purpose is not to determine if one doublet is better than another. Rather, this second purpose is to show that for all patients enrolled in this protocol who have been assigned a doublet based on their tumor's molecular analysis (molecular tailoring), treatment response will be better than would be expected compared to patients who have been treated in the past with no molecular tailoring.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Gemcitabine Gemzar Oxaliplatin Eloxatin Gemcitabine Gemzar 5-FU 5-fluorouracil Gemcitabine Gemzar Docetael taxotere Oxaliplatin Eloxatin 5-FU 5-Fluorourcil Leucovorin Docetaxel Taxotere Oxalipaltin Eloxatin Irinotecan CPT-11 5-FU 5-Fluorouracil Leucovorin Docetaxel Taxotere Irinotecan CPT-11

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically proven pancreatic adenocarcinoma with measurable disease
* Biopsy accessible tumor deposits
* ECOG performance status 0-2
* Age \>/= 18 years
* Subjects with no brain metastases or history of previously treated brain metastases
* Adequate hepatic, renal, and bone marrow function
* Partial thromboplastin time must be \</= 1.5 x upper normal limit of institution's normal range and INR \< 1.5
* Life expectancy \> 12 weeks
* Women of childbearing potential must have a negative seum pregnancy test within 14 days prior to initiation of treatment
* Subject is capable of understanding and complying with parameters as outlines in the protocol and able to sign and date the consents

* Active severe infection or known chronic infection with HIV or hepatitis B virus
* Cardiovascular disease
* Life threatening visceral disease or other severe concurrent disease
* Women who are pregnant, breastfeeding, or women of childbearing potential not using dual forms of effective contraception
* Anticipated patient survival under 3 months
* Patients receiving any other investigational agents
* History of allergic reactions attributed to compounds of similar chemical or biological composition to gemcitabine, oxaliplatin, 5-FU, docetaxel or irinotecan
* Uncontrolled intercurrent illness

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No